Table 4.
Clinical trials reported with mesenchymal stem cells (MSC) in the context of intervertebral disc degeneration (IVDD) based on data from May 2023 (www.clinicaltrials.com).
| Status | Type | Trial ID | Phase | Result |
|---|---|---|---|---|
| Completed 2017 | IVDD therapy with allogeneic MSC. Randomized, triple blind study. Spain | NCT01860417 | 1/2 | MSC vs. Mepivacaine not yet available in database. Reproducible cell expansion and satisfactory quality control tests (398) |
| Completed 2017 | Use of autologous BM-MSC in patients with lumbar IVDD. Open label. Spain | NCT01513694 | 1/2 | No results posted |
| Completed 2015 | Safety and preliminary efficacy of mesenchymal precursor cells in subjects with lumbar back pain. Randomized, double blind. United States, Australia | NCT01290367 | 2 | No results posted |
| Completed 2013 | Study of 3 doses of NeoFuse combined with MasterGraft granules in subjects requiring posterolateral lumbar fusion. Randomized, open label. United States | NCT00549913 | 1/2 | No results posted |
| Withdrawn 2015 | Autologous AD-MSC transplantation in patient with lumbar IVDD. Open label. Republic of Korea. | NCT01643681 | n/a | No results posted. Unwilling to continue clinical trials. |
| Withdrawn 2012 | Lumbar IVDD therapy with autologous BM-MSC. Open label. No location data. | NCT02440074 | 1/2 | No results posted. Not funded. Administrative formalities. |
| Withdrawn 2022 | MSC for lumbar IVDD. Randomized, open label. Unites States | NCT03692221 | 1 | No results posted. Stalled due to COVID-19 |
| Withdrawn 2011 | Safety and efficacy of NeoFuse in subjects requiring posterolateral lumbar fusion. Open label. United States | NCT00810212 | 1/2 | No results posted. Withdrawn for better study design (Mesoblast). |
AD-MSC, adipose-derived mesenchymal stromal cell; BM-MSC, bone marrow derived mesenchymal stem cell.